PMID- 31572499
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1758-5996 (Print)
IS  - 1758-5996 (Electronic)
IS  - 1758-5996 (Linking)
VI  - 11
DP  - 2019
TI  - Consensus recommendations for management of patients with type 2 diabetes 
      mellitus and cardiovascular diseases.
PG  - 80
LID - 10.1186/s13098-019-0476-0 [doi]
LID - 80
AB  - The recent American Diabetes Association and the European Association for the 
      Study of Diabetes guideline mentioned glycaemia management in type 2 diabetes 
      mellitus (T2DM) patients with cardiovascular diseases (CVDs); however, it did not 
      cover the treatment approaches for patients with T2DM having a high risk of CVD, 
      and treatment and screening approaches for CVDs in patients with concomitant 
      T2DM. This consensus guideline undertakes the data obtained from all the 
      cardiovascular outcome trials (CVOTs) to propose approaches for the T2DM 
      management in presence of CV comorbidities. For patients at high risk of CVD, 
      metformin is the drug of choice to manage the T2DM to achieve a patient specific 
      HbA1c target. In case of established CVD, a combination of glucagon-like 
      peptide-1 receptor agonist with proven CV benefits is recommended along with 
      metformin, while for chronic kidney disease or heart failure, a sodium-glucose 
      transporter proteins-2 inhibitor with proven benefit is advised. This document 
      also summarises various screening and investigational approaches for the major CV 
      events with their accuracy and specificity along with the treatment guidance to 
      assist the healthcare professionals in selecting the best management strategies 
      for every individual. Since lifestyle modification and management plays an 
      important role in maintaining the effectiveness of the pharmacological therapies, 
      authors of this consensus recommendation have also briefed on the patient-centric 
      non-pharmacological management of T2DM and CVD.
CI  - (c) The Author(s) 2019.
FAU - Bashier, Alaaeldin
AU  - Bashier A
AUID- ORCID: 0000-0001-8101-1833
AD  - 1Department of Endocrinology, Dubai Health Authority, Dubai Hospital, P.O. Box 
      94132, Dubai, UAE. ISNI: 0000 0004 1796 7314. GRID: grid.414162.4
FAU - Bin Hussain, Azza
AU  - Bin Hussain A
AD  - 1Department of Endocrinology, Dubai Health Authority, Dubai Hospital, P.O. Box 
      94132, Dubai, UAE. ISNI: 0000 0004 1796 7314. GRID: grid.414162.4
FAU - Abdelgadir, Elamin
AU  - Abdelgadir E
AD  - 1Department of Endocrinology, Dubai Health Authority, Dubai Hospital, P.O. Box 
      94132, Dubai, UAE. ISNI: 0000 0004 1796 7314. GRID: grid.414162.4
FAU - Alawadi, Fatheya
AU  - Alawadi F
AD  - 1Department of Endocrinology, Dubai Health Authority, Dubai Hospital, P.O. Box 
      94132, Dubai, UAE. ISNI: 0000 0004 1796 7314. GRID: grid.414162.4
FAU - Sabbour, Hani
AU  - Sabbour H
AD  - Cleveland Clinic Abu Dhabi, Heart and Vascular Institute, Al Maryah Island, Abu 
      Dhabi, UAE.
FAU - Chilton, Robert
AU  - Chilton R
AD  - 3Division of Cardiology, University of Texas Health Science Center, Audie L 
      Murphy VA Hospital, San Antonio, TX USA. ISNI: 0000 0004 0617 9080. GRID: 
      grid.414059.d
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190926
PL  - England
TA  - Diabetol Metab Syndr
JT  - Diabetology & metabolic syndrome
JID - 101488958
PMC - PMC6761728
OTO - NOTNLM
OT  - CVDs
OT  - CVOTs
OT  - Consensus
OT  - HF
OT  - T2DM
COIS- Competing interestsThe authors declare that they have no competing interests.
EDAT- 2019/10/02 06:00
MHDA- 2019/10/02 06:01
PMCR- 2019/09/26
CRDT- 2019/10/02 06:00
PHST- 2019/07/10 00:00 [received]
PHST- 2019/09/19 00:00 [accepted]
PHST- 2019/10/02 06:00 [entrez]
PHST- 2019/10/02 06:00 [pubmed]
PHST- 2019/10/02 06:01 [medline]
PHST- 2019/09/26 00:00 [pmc-release]
AID - 476 [pii]
AID - 10.1186/s13098-019-0476-0 [doi]
PST - epublish
SO  - Diabetol Metab Syndr. 2019 Sep 26;11:80. doi: 10.1186/s13098-019-0476-0. 
      eCollection 2019.